Arnaud G L'Huillier1, Yacine Abed2, Tom J Petty3, Samuel Cordey1, Yves Thomas1, Xavier Bouhy2, Manuel Schibler1, Audrey Simon4, Yves Chalandon4, Christian van Delden5, Evgeny Zdobnov3, Patricia Boquete-Suter1, Guy Boivin2, Laurent Kaiser6. 1. Laboratory of Virology, Divisions of Infectious Diseases and Laboratory Medicine. 2. Centre Hospitalier Universitaire de Québec and Université Laval, Quebec City, Canada. 3. Department of Genetic Medicine and Development, University of Geneva Medical School Swiss Institute of Bioinformatics, University of Geneva, Switzerland. 4. Division of Hematology, Department of Internal Medicine Specialties, University of Geneva Hospitals. 5. Division of Infectious Diseases, Department of Internal Medicine Specialties, University of Geneva Hospitals. 6. Laboratory of Virology, Divisions of Infectious Diseases and Laboratory Medicine University of Geneva Medical School, University of Geneva, Switzerland.
Abstract
BACKGROUND: An influenza A(H1N1)pdm09 infection was diagnosed in a hematopoietic stem cell transplant recipient during conditioning regimen. He was treated with oral oseltamivir, later combined with intravenous zanamivir. The H275Y neuraminidase (NA) mutation was first detected, and an E119D NA mutation was identified during zanamivir therapy. METHODS: Recombinant wild-type (WT) E119D and E119D/H275Y A(H1N1)pdm09 NA variants were generated by reverse genetics. Susceptibility to NA inhibitors (NAIs) was evaluated with a fluorometric assay using the 2'-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA) substrate. Susceptibility to favipiravir (T-705) was assessed using plaque reduction assays. The NA affinity and velocity values were determined with NA enzymatic studies. RESULTS: We identified an influenza A(H1N1)pdm09 E119D mutant that exhibited a marked increase in the 50% inhibitory concentrations against all tested NAIs (827-, 25-, 286-, and 702-fold for zanamivir, oseltamivir, peramivir, and laninamivir, respectively). The double E119D/H275Y mutation further increased oseltamivir and peramivir 50% inhibitory concentrations by 790- and >5000-fold, respectively, compared with the WT. The mutant viruses remained susceptible to favipiravir. The NA affinity and velocity values of the E119D variant decreased by 8.1-fold and 4.5-fold, respectively, compared with the WT. CONCLUSIONS: The actual emergence of a single NA mutation conferring pan-NAI resistance in the clinical setting reinforces the pressing need to develop new anti-influenza strategies.
BACKGROUND: An influenza A(H1N1)pdm09 infection was diagnosed in a hematopoietic stem cell transplant recipient during conditioning regimen. He was treated with oral oseltamivir, later combined with intravenous zanamivir. The H275Y neuraminidase (NA) mutation was first detected, and an E119D NA mutation was identified during zanamivir therapy. METHODS: Recombinant wild-type (WT) E119D and E119D/H275Y A(H1N1)pdm09 NA variants were generated by reverse genetics. Susceptibility to NA inhibitors (NAIs) was evaluated with a fluorometric assay using the 2'-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA) substrate. Susceptibility to favipiravir (T-705) was assessed using plaque reduction assays. The NA affinity and velocity values were determined with NA enzymatic studies. RESULTS: We identified an influenza A(H1N1)pdm09 E119D mutant that exhibited a marked increase in the 50% inhibitory concentrations against all tested NAIs (827-, 25-, 286-, and 702-fold for zanamivir, oseltamivir, peramivir, and laninamivir, respectively). The double E119D/H275Y mutation further increased oseltamivir and peramivir 50% inhibitory concentrations by 790- and >5000-fold, respectively, compared with the WT. The mutant viruses remained susceptible to favipiravir. The NA affinity and velocity values of the E119D variant decreased by 8.1-fold and 4.5-fold, respectively, compared with the WT. CONCLUSIONS: The actual emergence of a single NA mutation conferring pan-NAI resistance in the clinical setting reinforces the pressing need to develop new anti-influenza strategies.
Authors: Ha T Nguyen; Alicia M Fry; P Ann Loveless; Alexander I Klimov; Larisa V Gubareva Journal: Clin Infect Dis Date: 2010-10-15 Impact factor: 9.079
Authors: A C Hurt; Y M Deng; J Ernest; N Caldwell; L Leang; P Iannello; N Komadina; R Shaw; D Smith; D E Dwyer; A R Tramontana; R T Lin; K Freeman; A Kelso; I G Barr Journal: Euro Surveill Date: 2011-01-20
Authors: Samuel B Graitcer; Larisa Gubareva; Laurie Kamimoto; Saumil Doshi; Meredith Vandermeer; Janice Louie; Christine Waters; Zack Moore; Katrina Sleeman; Margaret Okomo-Adhiambo; Steven A Marshall; Kirsten St George; Chao Yang Pan; Jennifer M LaPlante; Alexander Klimov; Alicia M Fry Journal: Emerg Infect Dis Date: 2011-02 Impact factor: 6.883
Authors: Linghui Li; Yan Chai; Weiyu Peng; Delin Li; Litao Sun; George Fu Gao; Jianxun Qi; Haixia Xiao; William Jun Liu; Mark von Itzstein; Feng Gao Journal: Proc Natl Acad Sci U S A Date: 2022-10-03 Impact factor: 12.779
Authors: Ju Hwan Jeong; Won-Suk Choi; Khristine Joy C Antigua; Young Ki Choi; Elena A Govorkova; Richard J Webby; Yun Hee Baek; Min-Suk Song Journal: J Virol Date: 2020-12-09 Impact factor: 5.103
Authors: Simone E Adams; Vladimir Y Lugovtsev; Anastasia Kan; Nicolai V Bovin; Raymond P Donnelly; Natalia A Ilyushina Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Chiara Medaglia; Arnaud Charles-Antoine Zwygart; Paulo Jacob Silva; Samuel Constant; Song Huang; Francesco Stellacci; Caroline Tapparel Journal: Microorganisms Date: 2021-06-01